Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.22M | 7.46M | 6.75M | 4.76M | 3.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.02M | 41.79M | 26.64M | 20.63M | 19.75M |
| Operating Income | -32.02M | -41.79M | -26.64M | -20.63M | -19.75M |
| Income Before Tax | -27.34M | -36.77M | -20.77M | -17.48M | -17.05M |
| Income Tax Expenses | 52.00K | 72.00K | 186.00K | -- | -- |
| Earnings from Continuing Operations | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.39M | -36.85M | -20.96M | -17.48M | -17.05M |
| EBIT | -32.02M | -41.79M | -26.64M | -20.63M | -19.75M |
| EBITDA | -32.00M | -41.77M | -26.62M | -20.61M | -19.74M |
| EPS Basic | -0.50 | -0.68 | -0.39 | -1.60 | -19.01 |
| Normalized Basic EPS | -0.31 | -0.42 | -0.24 | -1.00 | -11.88 |
| EPS Diluted | -0.50 | -0.68 | -0.39 | -1.60 | -19.01 |
| Normalized Diluted EPS | -0.31 | -0.42 | -0.24 | -1.00 | -11.88 |
| Average Basic Shares Outstanding | 54.54M | 54.46M | 54.42M | 10.90M | 896.70K |
| Average Diluted Shares Outstanding | 54.54M | 54.46M | 54.42M | 10.90M | 896.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |